Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1β production in a cancer-induced pain model in mice

Yuki Orikawa1*, Hiroki Kato2, Koichi Seto1, Nobuyoshi Kobayashi1, Koji Yoshinaga1, Hiroki Hamano1, Yuko Hori1, Tim Meyer3, Mineo Takei1

Abstract

Background: Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in combination with gemcitabine prolonged the survival period in a lethal pancreatic cancer xenograft model in mice. In a phase Ib/IIa clinical study, Z-360 treatment displayed a trend of reduced pain in patients with advanced pancreatic cancer in combination with gemcitabine including analgesics such as opioids. Here, we investigated the mechanism of analgesic action of Z-360 in a severe cancer-induced pain model in mice, which is considered to be opioid-resistant, by examining ephrin B1 gene expression, N-methyl-D-aspartate receptor NR2B subunit phosphorylation, and interleukin-1β (IL-1β) production.

Results: In a mouse model of cancer-induced pain, ephrin B1 gene expression in dorsal root ganglia (DRGs) and the phosphorylation of NR2B in the spinal cord were induced. Z-360 treatment inhibited both ephrin B1 gene expression and the phosphorylation of NR2B. In addition, IL-1β production increased in the cancer-inoculated hind paw of mice, but could be suppressed by treatment with Z-360. Moreover, we observed that the CCK1 receptor antagonist devazepide similarly suppressed up-regulation of ephrin B1 gene expression and IL-1β production, and that the intraperitoneal injection of sulfated CCK-8 induced the production of IL-1β in the cancer-inoculated region.

Conclusions: We have identified a novel pain cascade, in which IL-1β production in cancer-inoculated regions induces ephrin B1 gene expression in DRGs and then ephrin B1 enhances the tyrosine phosphorylation of NR2B via Eph B receptor in the spinal cord. Notably, Z-360 relieves cancer-induced pain by preventing this pain cascade through the suppression of IL-1β production, likely via the blockade of CCK1 receptor. The pre-clinical results presented here support the analgesic action of Z-360 in pancreatic cancer patients with severe, opioid-resistant pain. Pre-clinical and clinical results have demonstrated that Z-360 combined with gemcitabine represents a promising pancreatic cancer therapy approach with characteristic analgesic effects in addition to the prolongation of survival.

* Correspondence: yuki-orikawa@zeria.co.jp
1 Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1 Numagami, Oshikiri, Kumagaya-shi, Saitama, Japan
Full list of author information is available at the end of the article

© 2010 Orikawa et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Background**

Patients with cancer develop diverse symptoms, among which pain is a major factor that can drastically reduce quality of life [1-3]. Pancreatic cancer, in particular, is often accompanied by severe pain, with 90% of patients reporting significant pain [4]. Cancer-induced pain is typically relieved with opioids, such as morphine, non-opioid analgesics, such as acetaminophen, and nonsteroidal anti-inflammatory drugs; however, these drugs are not uniformly effective and undesirable side effects often limit their use [5]. For these reasons, it is therefore desirable to develop novel medical agents with increased efficacy and safety for combating cancer-induced pain.

Z-360, calcium bis [(R)-(−)-3-[3-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl]ureido]benzoate], is an orally active 1,5-benzodiazepine derivative cholecystokinin-2 (CCK2)/gastrin receptor antagonist that is currently under development for the treatment of pancreatic cancer [6]. In pre-clinical studies, Z-360 inhibited pancreatic cancer growth and prolonged survival in combination with gemcitabine, a first line drug for the treatment of pancreatic cancer, in mouse pancreatic cancer xenograft models [7-9]. Z-360 was safe, well tolerated, and showed a trend towards reduced pain in phase Ib/IIa clinical study patients with advanced pancreatic cancer when used in combination with gemcitabine and analgesics, such as opioids [6].

In a previous pre-clinical study, we evaluated the analgesic effect of Z-360 using a mouse model of cancer-induced pain that was generated by the orthotopic transplantation of B16/BL6 melanoma cells into the plantar region of the right hind paw of C57BL/6 mice [10]. This model induced licking behaviour (an indicator of spontaneous pain), and mechanical allodynia and hyperalgesia in the periphery of the melanoma mass were observed from approximately day 10 after transplantation [11,12], with intensities that were a notable feature of this model. The mechanical allodynia and hyperalgesia occurring at a late phase in this model were considered to be resistant to existing analgesics, including opioids and adjuvant analgesics [11-13], which is similar to the resistance displayed by moderate-to-severe pain of cancer patients. Therefore, the effects of Z-360 on cancer-induced pain were examined in this model, and it was found that it displayed an analgesic effect that was attributed to the blockade of CCK1 receptor [10]. Moreover, we observed that the combination of Z-360 and morphine were more effective than when each were administered alone. For these reasons, the analgesic effect of Z-360 on cancer-induced pain model in mice is considered to be associated with the observed clinical benefit of Z-360 for pain relief against opioid-resistant pancreatic cancer pain [6].

Recent studies suggest that ephrin B-Eph B receptor signalling in dorsal root ganglia (DRGs) contributes to activation of the N-methyl-D-aspartate (NMDA) receptor [14,15] and plays a critical role in neuropathic pain [16,17] and inflammatory hyperalgesia [14]. We speculate that ephrin B-Eph B receptor signalling in DRGs is also involved in cancer-induced pain, as this type of pain is both neuropathic and inflammatory [12]. Interleukin-1β (IL-1β) is a major inflammatory cytokine that has diverse effects on the immune system and is considered to be relevant to cancer development, owing to high levels of serum IL-1β [18,19] and elevated gene expression [20,21] in cancer patients. Recently, it was reported that IL-1β gene promoter single nucleotide polymorphisms (IL-1β secretory phenotype) are associated with an increased risk for pancreatic cancer [19] and that IL-1β participates in opioid-resistant pain, such as bone cancer and neuropathic pain [22-27]. Zhang et al. also reported that spinal IL-1β facilitated bone cancer pain [24], and the intraneural administration of IL-1β into rat sciatic nerves induced signs of neuropathic pain [22]. Conversely, the administration of IL-1β inhibitors exhibited anti-hypernociceptive action in different models of neuropathic pain [26,27]. Based on these results, IL-1β is considered to be a critical factor in the development of opioid-resistant pain, such as cancer-induced pain.

In this study, we attempted to determine the mechanism by which Z-360 mediates analgesic effects using a mouse model of cancer-induced pain and examining ephrin B-Eph B receptor signalling in DRGs, NMDA receptor NR2B subunit phosphorylation, and IL-1β production.

**Results**

Ephrin B1 gene expression in DRGs was induced in a cancer-induced pain model in mice

In order to identify the factors that are associated with cancer-induced pain, we first examined the expression of several genes involved in the ephrin signalling pathway, including ephrin A1, ephrin A2, ephrin B1, ephrin B2, and the Eph A1 and Eph B1 receptors, in the DRGs of six-week old C57BL/6 mice injected with B16/BL6 melanoma cells into the plantar region of the right hind paw. As determined by quantitative real-time RT-PCR, the gene expression of ephrin B1 in lumbar (L) 4-5 DRGs was induced 1.8 fold in cancer-induced pain mice compared to normal control mice on day 15 after melanoma transplantation (p < 0.001) (Figure 1A); however,
no change was observed for the Eph B1 receptor (Figure 1B). The expression of other examined genes (ephrin A1, A2, B2 and Eph A1 receptor) were also not induced (data not shown).

Effect of Z-360 on ephrin B1 gene expression in a cancer-induced pain model in mice
After demonstrating that ephrin B1 gene expression was up-regulated in DRGs of mice injected with B16/BL6 melanoma cells, the effect of Z-360 treatment was examined. Z-360 (100 mg/kg) was administered orally once a day beginning on day 7 to day 14 after transplantation, because the analgesic effect of Z-360 in cancer-induced pain was confirmed most strongly by repeated administration of a dose of 100 mg/kg [10]. On day 14 after transplantation, the expression of the ephrin B1 and Eph B1 receptor genes in L4-5 DRGs were examined (Figure 2A, B). Repeated administration of Z-360 suppressed the gene expression of ephrin B1 by 70.7% compared with the vehicle-treated group in cancer-induced pain mice (p < 0.001) (Figure 2A). The gene expression of the Eph B1 receptor was unchanged in all of the test groups (Figure 2B).

Effect of Z-360 on NR2B phosphorylation in cancer-induced pain model in mice
Several tyrosine residues in the C-terminal cytoplasmic region of NR2B have been shown to be phosphorylated by Src family tyrosine kinases in vitro [28], with Tyr-1472 being the major phosphorylation site. As it has been reported that ephrin B2 induces phosphorylation of Tyr-1472 residues [14], we next investigated whether Tyr-1472 phosphorylation of NR2B was enhanced in the spinal cord of the mouse model of cancer-induced pain. The level of phosphorylated Tyr-1472 NR2B in the vehicle control in cancer-induced pain mice was 210% higher than the normal control samples (p < 0.05) (Figure 3A, B); however, the repeated administration of Z-360 (100 mg/kg) once a day from day 7 to 14 after transplantation suppressed phosphorylation by 62.5% compared with the vehicle control (p < 0.05) (Figure 3A, B).

IL-1β levels increased in the cancer-inoculated region of the right hind paw in the mouse model of cancer-induced pain and was suppressed by Z-360 treatment
To investigate the effects of increased gene expression of ephrin B1 in the mouse model of cancer-induced pain, we examined the change in the inflammatory mediator IL-1β in the cancer-inoculated region of the right hind paw by double sandwich enzyme-linked immunosorbent assay (ELISA). We found that IL-1β levels were significantly increased in these regions of cancer-induced pain mice compared with normal mice (p < 0.01) (Figure 4A). However, the administration of Z-360 (100 mg/kg) once a day from day 7 to 14 after transplantation significantly reduced the levels of IL-1β protein in the cancer-inoculated region by 54.3% compared to the vehicle-treated group in cancer-induced pain mice.
This data suggested that Z-360 suppressed the production of IL-1β. In addition, the effect of Z-360 on tumour size was assessed at day 14 after transplantation. The tumour size of the Z-360-treated group was similar to that of vehicle-treated group (data not shown), indicating that Z-360 had no effect on tumour size in this cancer-induced pain model in mice.

Effect of IL-1β injection into the right hind paw on the gene expression of ephrin B1

To confirm whether IL-1β induced the gene expression of ephrin B1 in L4-5 DRGs, we injected IL-1β (300 and 1000 pg/paw) directly into the plantar region of the right hind paw of eight-week old C57BL/6 mice, and examined the expression of the ephrin B1 and Eph B1 receptor genes in L4-5 DRGs after 60 min. It was revealed that IL-1β injection (1000 pg/paw) into the plantar region of the right hind paw significantly induced the gene expression of ephrin B1 in L4-5 DRGs (p < 0.05), but not the Eph B1 receptor (Figure 5A, B). The injection IL-1β at 300 pg/paw had no effect on either ephrin B1 or Eph B1 receptor gene expression.

Effects of devazepide on ephrin B1 gene expression and IL-1β production

In our previous study, repeated oral administration of devazepide, a CCK1 receptor antagonist, showed a similar anti-allodynic effect in the mouse model of cancer-induced pain to that of Z-360 [10]. Here, we examined the effects of devazepide on ephrin B1 gene expression in DRGs and the level of IL-1β in the cancer-inoculated region in the cancer-induced pain model in mice. Devazepide (10 mg/kg) was administered orally once a day from day 7 to 14 after transplantation, and gene expression of ephrin B1 and the Eph B1 receptor in L4-5 DRGs and the amount of IL-1β protein in the cancer-inoculated region were then measured. The repeated administration of devazepide significantly suppressed the expression of the ephrin B1 gene compared with the vehicle-treated group in cancer-induced pain mice (p < 0.01) (Figure 6A); however, the gene expression of the Eph B1 receptor was unchanged in all of the test groups (Figure 6B).

The amount of IL-1β protein in the cancer-inoculated region was reduced by 25.8% in the devazepide-treated group compared with vehicle-treated group (Figure 6C). The p-value of the Wilcoxon test compared with the vehicle-treated group was 0.08. The effect of devazepide on tumour size was assessed at day 14 after transplantation and no differences in the tumour size were detected between the control and devazepide-treated group (data not shown).

Sulfated cholecystokinin-8 induced IL-1β production in the cancer-inoculated region

To determine whether CCK contributed to the increased levels of IL-1β in the cancer-inoculated region, we examined the effect of sulfated CCK-8 injection on IL-1β production. Sulfated CCK-8 (10 and 30 μg/kg)
was intraperitoneally injected into the mouse model of cancer-induced pain twice a day beginning from day 7 after transplantation, and the final injection was performed 30 min prior to the collection of paw samples on day 10. The levels of IL-1β protein in the cancer-inoculated regions were then measured by ELISA, which revealed that the administration of sulfated CCK-8 increased the amount of IL-1β protein compared with that of the vehicle-treated control group (p < 0.01) (Figure 7). The levels of IL-1β between the saline, 10 μg-, and 30 μg-sulfated CCK-8 treatment groups were 227.4, 862.0, and 719.1 pg/g tissue, respectively.

**Discussion**

In this study, we discovered a novel pain cascade associated with the analgesic action of Z-360 in a mouse model of cancer-induced pain. In this cascade, IL-1β production from cancer-inoculated regions induces the gene expression of ephrin B1 in DRGs, which then enhances the tyrosine phosphorylation of NR2B via Eph B receptor in the spinal cord, finally leading to pain. Z-360 was found to inhibit this pain cascade, suggesting that Z-360 reduces cancer-induced pain through the suppression of IL-1β production in cancer-inoculated regions, which in turn inhibits ephrin B1 gene expression, and tyrosine phosphorylation of NR2B. The pre-clinical results presented here indicate that Z-360 may provide relief against severe, opioid-resistant pain in patients with advanced pancreatic cancer.

In the cancer-induced pain model used in this study, it was reported that bradykinin and related peptides released from melanoma cells might cause spontaneous pain and allodynia [29]; however, we identified that the enhancement of IL-1β production, which may be predominantly released from immune cells invading tissues surrounding tumors, is another potential factor for causing pain. We demonstrated that IL-1β increased in cancer-inoculated regions and induced the expression of the ephrin B1 gene in the periphery of DRGs. We also found that the tyrosine phosphorylation of NR2B in the spinal cord was enhanced in the cancer-induced pain model in mice. The activation of the NMDA receptor is essential for the development of chronic inflammatory and neuropathic pain [30-32]. As our present data suggests that the novel pain cascade may be important for the development of cancer-induced pain, we propose that the components of this novel pain cascade, IL-1β (cancer-inoculated region) → ephrin B1 (DRGs) → NR2B (spinal cord), represent potential drug targets for the treatment of cancer-induced pain.

*In vitro* experiments have revealed that Z-360 has affinity for both recombinant human CCK2 and CCK1 receptors, with K₅₅ of 0.47 and 316 nM, respectively [7]. In our previous study, the analgesic effect of CCK1 receptor antagonist, devazepide, was also observed after repeated administration to the mouse model of cancer-induced pain [10]. Here, devazepide (10 mg/kg) reduced the level of IL-1β protein in cancer-inoculated regions, and significantly suppressed the gene expression of ephrin B1 in DRGs to a similar degree as Z-360. Cunningham et al. reported that CCK induces the production of inflammatory cytokines, including IL-1β, in monocytes from peripheral blood [33]. We also confirmed here that the intraperitoneal injection of sulfated CCK-8 (10 and
30 μg/kg resulted in an increase in IL-1β production in cancer-inoculated regions. Taken together, these results suggest that Z-360 is able to suppress IL-1β production via the blockade of CCK1 receptor.

In a previous pre-clinical study, Z-360 also exhibited analgesic effects on formalin-induced pain [10], and Honore et al. demonstrated that IL-1αβ gene-deficient mice display reduced nociceptive sensitivity to formalin-induced pain [23]. Although the detailed mechanisms...
are unclear, we speculate that Z-360 inhibits formalin-induced pain via the suppression of IL-1β production. It is also possible that other factors besides the suppression of IL-1β production participate in the analgesic effects of Z-360 in these pain models. The group of Grossi et al. reported that novel 1,5-benzodiazepine derivatives, such as Z-360, display analgesic and/or anti-inflammatory properties in spite of lacking affinities for central and peripheral benzodiazepine receptors [34,35]. A few of the examined derivatives showed an analgesic effect on acetic acid-induced writhing in mice, whereas other derivatives inhibited leukocyte migration via the suppression of nociceptive and/or inflammatory mediators, such as IL-6 and prostaglandin E2, in a carrageenan-induced air pouch model in mice. Furthermore, although the target molecules of these activities were not specified, it was found that a few derivatives had both analgesic and anti-inflammatory activities with low acute toxicity. These results indicate that Z-360 may be able to mediate analgesic action through other mechanisms in addition to the inhibition of IL-1β production.

Recently, a number of 1,5-benzodiazepine derivatives have been developed as drug candidates for diseases associated with pain [36,37], inflammation [38,39], nerve injury [40], and cardiovascular disorders [41]. Due to the related nature of their structures, the characterised chemical structure of Z-360 can provide important information for the design and development of innovative analgesics and anti-inflammatory agents.

In summary, we have identified a novel pain cascade, IL-1β (cancer-inoculated region) → ephrin B1 (DRGs) → NR2B (spinal cord) → pain, that may be responsible for the development of opioid-resistant pain in the mouse model of cancer-induced pain. Moreover, Z-360 inhibited the novel pain cascade through the suppression of IL-1β production. Accordingly, we consider that...
the suppression of IL-1β production by Z-360 was critical for its ability to alleviate cancer-induced pain in a previous clinical study [6].

Conclusions
This pre-clinical study identified a novel pain cascade involving the release of IL-1β from a cancer-inoculated region, induction of ephrin B1 gene expression in DRGs, and subsequent enhancement of tyrosine phosphorylation of NR2B in the spinal cord. Notably, the oral administration of Z-360 inhibited the novel pain cascade through the suppression of IL-1β production. We conclude that the pre-clinical results presented here support the relief action of Z-360 against severe, opioid-resistant pain in patients with advanced pancreatic cancer. Preclinical and clinical results have demonstrated that Z-360 combined with gemcitabine is a safe and promising pancreatic cancer drug with characteristic analgesic effects in addition to the prolongation of survival.

Methods

Animals
Five and seven-week-old male C57BL/6NCrlCrlj (C57BL/6) mice were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan). Mice were kept under controlled temperature (23 ± 3°C), humidity (55 ± 20%), and lighting (lights on at 7:00 AM and off at 7:00 PM) conditions, and food and water were available ad libitum. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Zeria Pharmaceuticals Central Research Laboratories. Samplings were carried out between 10:00 AM and 4:00 PM.

Drug
Z-360 was synthesized at the Central Research Laboratories of Zeria Pharmaceutical Co., Ltd. (Kumagaya, Japan). Devazepide was purchased from Tocris Bioscience Inc. (St. Louis, MO, USA). Z-360 and devazepide were resuspended in a 0.5% (w/v) carboxymethyl cellulose sodium solution before use.

Mouse model of cancer-induced pain
A mouse model of cancer-induced pain was made according to the method of Sasamura et al [11]. Briefly, B16/BL6 melanoma cells derived from C57BL/6 mice (Cell Resource Center for Biomedical Research, Tohoku University, Sendai, Japan) were cultured in RPMI1640 medium containing 10% fetal bovine serum at 37°C and a humidified atmosphere of 5% CO2. Cells (2 × 10^5 cells/20 μL) were injected into the plantar region of the right hind paw of six-week old C57BL/6 mice. Z-360 (100 mg/10 mL/kg) or devazepide (10 mg/10 mL/kg) was administered orally once a day from day 7 to 14 after transplantation, and paw withdrawal thresholds were measured on day 7 and 14 after transplantation, and paw withdrawal thresholds were measured on day 7 and 14. Z-360 or devazepide (at the above-mentioned concentrations) was administered orally 60 min prior to tissue sampling on day 14 after transplantation.

Preparation of DRG samples for gene expression analysis
On day 14 after transplantation, L4 and L5 DRG samples were taken from normal mice and the cancer-induced pain mouse model. Two DRG bodies for each sample were pooled and then homogenized with lysis buffer from an RNeasy Micro Kit (QIAGEN, Hilden, Germany) using a Tissue Lyser (QIAGEN) for the preparation of total RNA.

Real-time quantitative RT-PCR
Total RNA was prepared from tissue lysate using an RNeasy Micro Kit (QIAGEN). After purification, the amount of RNA was measured spectrophotometrically using OD260, and the quality of RNA was checked by gel electrophoresis and spectrophotometric analysis using OD260/280. Total RNA (100 ng) was converted into first-strand cDNA by PrimeScript RT Reagent Kit (Takara Bio Inc., Otsu, Japan). The resulting first-strand

![Figure 7](http://www.molecularpain.com/content/6/1/72)

**Figure 7** Effect of sulfated CCK-8 on IL-1β production in the cancer-inoculated region. B16/BL6 cells were injected into the plantar region of the right hind paw of C57BL/6 mice, and sulfated CCK-8 (10 or 30 μg/kg) was then administered by intraperitoneal injection twice a day from day 7 after transplantation. On day 10 after transplantation, a final dose of sulfated CCK-8 was administered to mice 30 min prior to the collection of right hind paw samples, which were the homogenized and subjected to ELISA for the measurement of IL-1β. The data are reported as the mean ± S.E. (n = 11-12). ##, p < 0.01, versus saline (non-parametric Dunnett’s test).
cDNAs were subjected to real-time quantitative RT-PCR with Absolute™ QPCR ROX Mix (Thermo Fisher Scientific, Waltham, MA, U.S.A.) and TaqMan probes for ephrin B1 (Mm00438666_m1) and the Eph B1 receptor (Mm00557961_m1), using an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, U.S.A.). The cycling parameters were 15 min at 95°C followed by 45 cycles of 15 sec at 95°C and 1 min at 60°C. The obtained data were normalized to the expression of GAPDH (Mm99999915_g1) and analyzed by the Comparative CT Method (Applied Biosystems).

Tyrosine phosphorylation of NR2B
The relative tyrosine phosphorylation of NR2B was examined by immunoprecipitation. For the analysis, the spinal cords from normal and cancer-induced pain model mice were rapidly removed on day 14 after transplantation. Z-360 (100 mg/kg) was administered orally once a day beginning from day 7 after transplantation. Tissues were homogenized in solubilization buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA (pH 8.0), 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 1 mM sodium vanadate (Na3VO4), 25 mM sodium fluoride (NaF), 1 mM PMSF, and protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, U.S.A.) using a Tissue Lyser (QIAGEN). After centrifugation at 12,000 rpm for 5 min at 4°C, the supernatants containing the proteins were collected and the protein concentrations were determined using the BCA Protein Assay (Bio-Rad Laboratories, Hercules, CA, U.S.A.). Equal amounts of proteins were added to 0.6 µg of rabbit anti-NR2B antibody (Millipore, Billerica, MA, U.S.A.) and gently shaken overnight at 4°C. The following morning, Dynabeads Protein G (Invitrogen, Carlsbad, CA, U.S.A.) were added to the samples which were then gently shaken for 1 h at 4°C. Beads were then rinsed in solubilization buffer and boiled in loading buffer (2% SDS, 50 mM Tris-HCl (pH 6.8), 200 mM β-mercaptoethanol, 10% glycerol, and 0.1% Bromophenol Blue) for 5 min. The protein-rich supernatants were separated on a 7.5% Ready-gel J (Bio-Rad Laboratories) and transferred to a polyvinylidene difluoride (PVDF) membrane using a Trans-Blot Cell System (Bio-Rad Laboratories). The membranes were blocked for 1 h at room temperature with 3% non-fat milk in Tris buffered saline containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.1% Tween20 (TBST) and then incubated overnight at 4°C with rabbit anti-phospho-tyr1472-NR2B antibody (1:1000, Upstate, Cambridge, U.K.). After washing with TBST, membranes were incubated for 1 h at room temperature with HRP-rec-Protein G (1:8000, Invitrogen). All antibodies were diluted in TBST. Protein bands were visualized using an Enhanced Chemi-Luminescence Detection Kit (ECL Plus, Amersham Pharmacia, Chalfont St.Giles, U.K.) followed by autoradiography using Hyperfilm (Amersham Pharmacia). The blots were then washed in TBST and stripped for 30 min in stripping buffer containing 2% SDS, 62.5 mM Tris-HCl (pH 6.8), and 100 mM β-mercaptoethanol. The membranes were washed twice in TBST for 30 min and then blocked for 1 h at room temperature with 3% non-fat milk in TBST. Membranes were reprobed for total NR2B by overnight incubation at 4°C with rabbit anti-NR2B antibody (Millipore). Blots were then washed, incubated for 1 h at room temperature with HRP-rec-Protein G (1:8000, Invitrogen), and visualized as above. Hyperfilms were scanned and captured using Adobe Photoshop Element 5.0 software (Adobe Systema Inc., Scion Jose, CA, U.S.A.) for densitometric quantification. We obtained the relative phosphotyrosin-1472-NR2B band density (relative pTyr1472-NR2B density) levels by normalizing the anti-phosphotyrosine immunoblot against the corresponding total NR2B immuno blot from identical samples.

IL-1β levels in the right hind paw
On day 14 after transplantation, we dissected the cancer-inoculated regions of right hind paw including B16/BL6 melanoma or normal as sample. After measuring their weight, samples were homogenized in 0.5 mL protein lysis buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA (pH 8.0), 1% NP-40, 1 mM sodium vanadate (Na3VO4), 1 mM PMSF, and protease inhibitor cocktail (Sigma-Aldrich) using an Ultra-Turrax T25 (Janke & Kunkel, IKA Werk, Staufen, Germany). After centrifugation at 3,000 rpm for 15 min at 4°C, supernatants containing the proteins were collected and IL-1β levels were determination by ELISA (R&D Systems, Minneapolis, MN, U.S.A.).

IL-1β-inducible gene expression analysis in DRGs
Recombinant mouse IL-1β (R&D systems) (5 µL, 300 or 1000 pg/paw) was injected into the plantar region of the right hind paw of eight-week old C57BL/6 mice. Sixty min after the injection, L4-5 DRG samples were removed and gene expression analysis and real-time quantitative RT-PCR were performed as described above.

Sulfated CCK-8-induced IL-1β production
In the mouse model of cancer-induced pain, intraperitoneal injection of 10 mL of sulfated CCK-8 per kg body weight (10 or 30 µg/kg, Peptide Institute, Inc., Osaka, Japan) was performed twice daily from day 7 after transplantation. On day 10, the amounts of IL-1β protein in the right hind paw samples were measured by ELISA as described above. Sulfated CCK-8 was administrated 30 min prior to the removal of the paw. In total, the injection of sulfated CCK-8 was performed seven times.
Statistical analysis

All data are expressed as the mean ± standard error (S.E.). Data were analyzed with SAS System Version 8.2 (SAS Institute Japan Ltd., Tokyo, Japan) using the t-test, Wilcoxon signed-rank test, and non-parametric Dunn-net’s test. Differences with a p-value of less than 0.05 were considered statistically significant.

Author details

1Department of Clinical Research, Zeria Pharmaceutical Co., Ltd., 2512-1 Namagami, Oshiki, Kumagaya-shi, Saitama, Japan. 2Department of Clinical Research, Zeria Pharmaceutical Co., Ltd., 10-11, Nishinobashi, Kobuncho, Chuo-ku, Tokyo, Japan. 3UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK.

Authors’ contributions

YO participated in the experimental design, carried out the experiments and data analysis, and drafted the manuscript. KS participated in the experimental design, helped perform the experiments, provided data interpretation, and finalized the manuscript. NK, HH, and YH helped perform the experiments. HK, KY, TM, and MT finalized the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 29 July 2010 Accepted: 28 October 2010 Published: 28 October 2010

References

1. Portenoy RK, Lesage P: Management of cancer pain. Lancet 1999, 353:1695-1700.
2. Caraceni A, Portenoy RK: An international survey of cancer pain characteristics and syndromes. Pain 1999, 82:263-274.
3. Laird B, Colvin L, Fallon M: Management of cancer pain: basic principles and neuropathic cancer pain. European Journal of Cancer 2008, 44:1079-1082.
4. Foley KM: Management of cancer pain: basic principles and pharmacologic management of pancreatic cancer pain. Journal of Pain and Symptom Management 1988, 3:176-187.
5. Negus SS, Vanderah TW, Brandt MR, Bilsky EJ, Becerra L, Borsok D: Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. The Journal of Pharmacology and Experimental Therapeutics 2006, 319:507-514.
6. Meyer T, Caplin ME, Palmer DH, Valle JW, Larvin M, Wates JS, Coxon F, Bruno V: Interaction between ephrins/Eph receptors and excitatory amino acid receptors: possible relevance in the regulation of synaptic plasticity and in the pathophysiology of neuronal degeneration. Journal of Neurochemistry 2006, 98:1-10.
7. Song XJ, Zheng JH, Wu C, Ghayur T, Iwakura Y, Calò L, Cinque C, Patane M, Schillaci D, Battaglia G, Melchiorri D, Nicoletti F, Carmi Y, Song X, Apte RN, Dotan S, Patients with advanced pancreatic cancer.
8. Kabir S, Grant C, Dark AS: Level of interleukin-1. The Journal of Biological Chemistry 1988, 263:207-212.
9. Decker MW, Faltynek CR, Sullivan J, Jarvis MF: Interleukin-1β receptor signalling contributes to neuropathic pain by regulating neural excitability and spinal synaptic plasticity in rats. Pain 2008, 139:168-180.
10. Fujii M, Andoh T, Ohashi K, Akira S, Kurasaki Y: Roles of kinin B1 and B2 receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice. European Journal of Pain 2009, 13:388-394.
30. Parsons CG: NMDA receptors as targets for drug action in neuropathic pain. European Journal of Pharmacology 2001, 429:71-78.
31. Petrenko AB, Yamakura T, Baba H, Shimoji K: The role of N-Methyl-D-Aspartate (NMDA) receptors in pain: a review. Anesthesia and analgesia 2003, 97:1108-1116.
32. Guo W, Wei F, Zou S, Robbins MT, Sugio S, Iekeda T, Tu JC, Worley PF, Dubner R, Ren K: Group I metabotropic glutamate receptor NMDA receptor coupling and signaling cascade mediate spinal dorsal horn NMDA receptor 2B tyrosine phosphorylation associated with inflammatory hyperalgesia. The Journal of Neuroscience 2004, 24:9161-9173.
33. Cunningham ME, Shaw-Stiffler TA, Bernstein LH, Tingtithella TJ, Claus RE, Brogan DA, McMillen MA: Cholecytokinin-stimulated monocytes produce inflammatory cytokines and eicosanoids. The American Journal of Gastroenterology 1995, 90:621-626.
34. Fruscella P, Sottocorno M, Bracci MD, Diomede L, Piccarini N, Cagnotto A, Grossi G, Romano M, Meninini T, Roma G: 1,5-Benzodiazepine tricyclic derivatives exerting anti-inflammatory effects in mice by inhibiting interleukin-6 and prostaglandin E2 production. Pharmacol Research 2001, 43:445-451.
35. Grossi G, Bracci MD, Roma G, Ballabeni V, Tognolini M, Calcina F, Barocelli E: 1,5-Benzodiazepines part XIII. Substituted 4H-[1,2,4] triazolo [4,3-a][1,5]benzodiazepine-5-aminos and 4H-imidazo[1,2-a][1,5] benzodiazepine-5 amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity. Eur J Med Chem 2002, 37:933-944.
36. Baba Y, Brown KC, Goehring RR, Tsuno N: Preparation of piperidinylquinoxalinedione derivatives and analogs as analgesics. 2008, Patent PCT International Application WO 2008089201.
37. Joergensen TK, Andersen KE, Andersen HS, Hohlweg R, Madsen P, Olesen UB: Novel heterocyclic compounds for treatment of pain and/or inflammation. 1996, Patent PCT International Application WO 96231497.
38. Feng J, Benedetti Y, Commercon A: New heterocyclic 2-alkoxy-3,4,5-trihydroxy-alkylamide derivatives are angiogenesis inhibitors-useful for the treatment of cancer, rheumatoid arthritis, osteoarthritis, inflammatory intestinal disorders, eye disorders, chronic inflammation and prioritis. 2007, Patent PCT International Application WO 2007135295.
39. Szewczyk JR, Donaldson KH: New benzodiazepine compounds are melanocortin MC4 agonists-useful for the treatment of obesity, diabetes mellitus, inflammation, depression and anxiety disorder. 2006, Patent PCT International Application WO 2006039991.
40. Flohr A, Jakob-Roetne R, Wood W: New 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives are gamma-secretase inhibitors -useful for the prevention and treatment of Alzheimer’s diseases. 2008, Patent PCT International Application WO 2008034735.
41. Oshima K, Oshiyama T, Taira S, Menjo Y, Yamabe H: New substituted benzodiazepine derivatives are Kv1.5 and GIRK1/4 channel inhibitors-useful for the treatment of arrhythmia. 2009, Patent PCT International Application WO 20090104819.

doi:10.1186/1744-8069-6-72
Cite this article as: Orikawa et al.: Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice. Molecular Pain 2010 6:72.